Q1 2026 · 13F-HR
M28 Capital Management LPholdings as filed
Filed 2026-05-14 · accession 0000902664-26-002442
$53.8M
Reported value
9
Positions
2026-03-31
Period end
The Brief · M28 Capital Management LP · Q1 2026
AI · grounded in 13F
M28 Capital Management LP reduced its position in TGTX by 45.3255%. The fund also trimmed holdings in RCKT and ARWR, both by 45.3249%. In total, the fund reduced seven of its nine positions without adding any new holdings to its $53.79 million portfolio.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $33.3M | 61.8% | 4,588,284 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $12.0M | 22.3% | 9,248,250 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $2.9M | 5.46% | 88,354 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $2.3M | 4.29% | 36,851 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $971,665 | 1.81% | 599,793 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $849,730 | 1.58% | 1,856,117 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $754,918 | 1.40% | 210,871 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $533,340 | 0.99% | 101,203 | Common | SOLE |
| 231269309 | CRIS | CURIS INC | $155,920 | 0.29% | 284,889 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.